Genetic, Microbiological and Behavioral Factors in Obesity

Recruiting now

Conditions studied: Obesity & Overweight, Obesity, Genetics

In brief

This study will assess the impact of genetic markers, microbiological (microbiome) and behavioral factors on tolerance, adherence and effectiveness of dual GLP1/GIP RA in the treatment of obesity. 200 consecutive patients who meet all inclusion and none of the exclusion criteria will be enrolled.

Key facts

Study ID

NCT07650149

Run by

Jan Kochanowski University

People needed

200

Starts

2026-05-23

Expected to finish

2028-05-01

Last updated by the study team

2026-06-16

Who can join

Age: 18 and older, up to 60. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age 18-60 years
• Consent to participate in the study and providing informed written consent
• Overweight or obese with a BMI >27

You may not qualify if…

• Contraindications to tirzepatide use:
• Type 1 or type 2 diabetes
• Pregnancy or breastfeeding
• Cancer
• Heart failure
• Expected lack of patient compliance
• Taking immunosuppressive medications, steroids, NSAIDs, antibiotics (within 2 weeks prior to sample collection),
• Autoimmune and inflammatory diseases, acute infectious diseases, AIDS, tuberculosis
• Mental illness
• Alcohol dependence syndrome
• Liver cirrhosis
• Post-myocardial infarction or stroke

Where it is running

• Waga Zmiany — Krakow, Poland (enrolling)
• Luxmed sp zoo — Warsaw, Poland (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.